End-stage kidney disease (ESKD) rates for Aboriginal and Torres Strait Islander people in remote areas are up to 30 times higher than the national average. Anaemia is a major complication of ESKD and often exacerbated by iron deficiency. It reduces quality of life and is associated with cardiovascular (CV) events and premature death. Erythropoietin (EPO) is the main agent used to correct anaemia but requires adequate iron stores to work effectively. Both EPO and IV iron are routine treatment for dialysis patients. Blood tests for ferritin and transferrin saturation are used to guide iron therapy. Ferritin is low with iron deficiency, but it is raised with ongoing inflammation or infection. Aboriginal and Torres Strait Islander dialysis patients have co-existing iron deficiency, high ferritin and ongoing inflammation. In this setting, there is no evidence to guide the use of IV iron and we do not understand the balance of benefits and harms of this routinely administered treatment.
The primary outcome is a composite outcome measure with:
1. All-cause death
2. Hospitalisation with a principal diagnosis of all-cause infection
• Pathology Results
• Comorbidities/Medical History
• Prescribed medications
This dataset is accessible by application through 'My Health Data Australia' (MyHDA), https://researchdata.edu.au/health
The platform is available to Australian Universities with AAF access.
Please note there may be data sharing restrictions, which will be described in MyHDA and on the trial registry.
Data Custodian and the Principal Investigator contact:
Prof Sandawana William Majoni